Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1749-6632.1995.tb24839.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multifunctions of Sustainable Chondroitin Sulfates with Predominant Subtypes and Low Molecular Weights on Neurite Outgrowth.
Biomacromolecules
January 2025
School of Life Science and Health Engineering, Jiangnan University, Wuxi 214122, China.
Three chondroitin sulfate (CS) analogues with predominant subtypes (A, C, and E) were prepared from engineered K4 combined with regioselective sulfation. CS with the designed sulfates as the main components was characterized by nuclear magnetic resonance spectroscopy, elementary analysis, and disaccharide analysis. CS prepared from the native or degraded capsular polysaccharide had molecular weights of 1.
View Article and Find Full Text PDFPerfluorooctane sulfonate attenuates IgE/Ag-stimulated mast cell activation and anaphylactic responses via activating SHP-1 pathway.
Chemosphere
January 2025
Department of Pharmacology/Toxicology, School of Medicine, Daegu Catholic University, Daegu, Republic of Korea. Electronic address:
Perfluorooctane sulfonate (PFOS), a widely distributed and persistent organic pollutant, is known to cause immune dysfunction. In a previous study, we reported that PFOS modestly increases mast cell activation. However, its effects on FcεRI (a high-affinity IgE receptor)-mediated mast cell activation, a pivotal process in inflammatory allergic reactions and innate immunity, have not been clearly demonstrated.
View Article and Find Full Text PDFBorderline Findings in -(2-[F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice.
J Nucl Med
January 2025
Institute of Neuroscience and Medicine (INM-3/INM-4/INM-5/INM-11), Forschungszentrum Jülich, Jülich, Germany.
One of the most common clinical indications for amino acid PET using the tracer -(2-[F]-fluoroethyl)-l-tyrosine (F-FET) is the differentiation of tumor relapse from treatment-related changes in patients with gliomas. A subset of patients may present with an uptake of F-FET close to recommended threshold values. The goal of this study was to investigate the frequency of borderline cases and the role of quantitative F-FET PET parameters in this situation.
View Article and Find Full Text PDFMetabolomic in severe traumatic brain injury: exploring primary, secondary injuries, diagnosis, and severity.
Crit Care
January 2025
Department of Critical Care Medicine, Cumming School of Medicine, Health Research Innovation Center (HRIC), University of Calgary, Room 4C64, 3280 Hospital Drive N.W., Calgary, AB, T2N 4Z6, Canada.
Background: Traumatic brain injury (TBI) is a major public health concern worldwide, contributing to high rates of injury-related death and disability. Severe traumatic brain injury (sTBI), although it accounts for only 10% of all TBI cases, results in a mortality rate of 30-40% and a significant burden of disability in those that survive. This study explored the potential of metabolomics in the diagnosis of sTBI and explored the potential of metabolomics to examine probable primary and secondary brain injury in sTBI.
View Article and Find Full Text PDFLeflunomide exerts neuroprotective effects in an MPTP‑treated mouse model of Parkinsonism.
Acta Neurobiol Exp (Wars)
January 2025
Ondokuz Mayıs University, School of Medicine, Department of Biochemistry, Samsun, Turkey.
Neuroinflammation and the immune response are recognized as significant mechanisms contributing to the progression and pathophysiology of Parkinson's disease (PD). Consequently, extensive research is being conducted on drugs targeting inflammation and immune response. Leflunomide, known for its anti‑inflammatory and immunomodulatory properties, is currently used as a disease‑modifying agent for the treatment of rheumatoid arthritis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!